Ascentage Pharma Announces the Fifth Orphan Drug Designation Granted to Bcl-2 Inhibitor APG-2575 by the US FDA, and the Tenth Obtained by the Company

SUZHOU,China and ROCKVILLE,Md.,Jan. 29,2021 --Ascentage Pharma (6855.HK),a globally focused,clinical-stage biotechnology company engaged in developing novel therapies for cancers,chronic hepatitis B (CHB),and age-related diseases,today announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to the company's novel Bcl-2 inhibitor,APG-2575,for the treatment of patients with follicular lymphoma (FL). This is the fifth ODD granted to the company's core asset APG-2575 by the US FDA,following the previous ODDs for the treatment of Waldenström macroglobulinemia (WM),chronic lymphocytic leukemia (CLL),multiple myeloma (MM),and acute myeloid leukemia (AML). To date,four of Ascentage Pharma's investigational drug candidates have been granted a total of ten ODDs by the US FDA,a record number for any Chinese biopharmaceutical company.

The term "orphan drugs" refers to pharmaceutical products developed for the prevention,diagnosis,and treatment of rare diseases or conditions. In the United States,an orphan indication is defined as a disease or condition with a prevalence of less than 200,000 patients in the country. Since the Orphan Drug Act was passed in 1983,the US government has provided incentives and policy support to encourage development of orphan drugs. Therapies granted ODDs by the FDA are qualified for various development incentives,including a tax credit on expenditures incurred in clinical studies,a waiver of the New Drug Application (NDA) fee,possible research grant awarded by the FDA,and most importantly,7 years of US market exclusivity upon approval.

FL is a heterogeneous disease and the second most common subtype of non-Hodgkin lymphoma (NHL) among adult patients in the US,accounting for about 20% of all NHL incidences[1]. Defined as a proliferation of malignant germinal center B cells,FL is also the most common subtype of indolent B-cell lymphoma[1],[2]. Although currently available therapies have significantly improved the overall survival of patients with FL,the disease still remains incurable[2],[3]. Majority of patients with FL relapse or experience disease progression after receiving the initial therapy,and experience multiple relapses thereafter requiring subsequent lines of therapy[4]. Despite the multiple treatment options for newly diagnosed and relapsed/refractory FL (r/r FL),FL still represents an unmet medical need,especially in those patients who are at high risk,relapsed early,have histological transformation,relapsed from available treatment options,or developed intolerance to available therapies.

APG-2575 is a novel,orally administered small-molecule Bcl-2‒selective inhibitor being developed by Ascentage Pharma. APG-2575 is designed to treat hematologic malignancies and solid tumors by selectively blocking antiapoptotic protein Bcl-2 to restore the normal apoptosis process in cancer cells. APG-2575 is the first China-developed Bcl-2 inhibitor entering clinical development in China. Previously,APG-2575 had received clearances and approvals for multiple Phase Ib/II clinical studies in China,Australia,and the US,and is currently being developed in a range of hematologic malignancies globally.

"This ODD from the FDA is the fifth one granted to APG-2575,a key drug candidate in our apoptosis-targeting pipeline,also the tenth obtained by the company. This latest designation enhances our leadership position in terms of the number of ODDs obtained by any Chinese biopharmaceutical company,further demonstrating our capabilities in innovation globally," said Dr. Yifan Zhai,Chief Medical Officer of Ascentage Pharma. "We hope the FDA's policy supports for orphan drug development will enable us to further accelerate the clinical development of APG-2575 and other ODD designated drug candidates in our pipeline,which hopefully can soon bring novel therapeutics to patients in need."

References

[1] Kridel R,Sehn L,Gascoyne D. Pathogenesis of follicular lymphoma. J Clin Invest. 2012 Oct;122(10):3424-31.

[2] Huet S,Sujobert P,Salles G. From genetics to the clinic: a translational perspective on follicular lymphoma. Nat Rev Cancer. 2018 Apr;18(4):224-239.

[3] Carbone A,et al. Follicular lymphoma. Nat Rev Dis Primers. 2019 Dec 12;5(1):83.

[4] Matasar M,et al. Follicular Lymphoma: Recent and Emerging Therapies,Treatment Strategies,and Remaining Unmet Needs. Oncologist. 2019 Nov;24(11):e1236-e1250.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused,CHB,and age-related diseases. On October 28,2019,Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates,including novel,highly potent Bcl-2,and dual Bcl-2/Bcl-xL inhibitors,as well as candidates aimed at IAP and MDM2-p53 pathways,and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US,and China. HQP1351,the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML),has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA,and a New Drug Application (NDA) for the drug candidate has been submitted in China. To date,Ascentage Pharma has obtained a total of ten ODDs from the US FDA for four of the company's investigational drug candidates.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law,we undertake no obligation to update or revise publicly any forward-looking statements,whether as a result of new information,future events,or otherwise,after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article,statements of,or references to,our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.